Sat, Sep 20, 2014, 8:52 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • migraine_jane migraine_jane Mar 28, 2013 9:25 AM Flag

    So what's this worth, alone?

    "50,000 cases of NTM lung disease were treated by physicians in the U.S. during 2011. There is no current FDA-approved treatment for NTM lung infection."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • If Arikace knocks out NTM in 84 days, big money because it represents a cure for an infectious disease that is only 30-40% curable. If it knocks out NTM in 30 days or less, it will be a panglobal antibiotic inside of two years. It depends upon the price point for one month of Rx. If you look at the other inhaled antibiotics, the price point is about $400 per month with discounts. But if the Pari device and a month's supply of Arikace is that beginning point for cures, I estimate the combined market to be the 50,000 treatment cases and another 50,000 who want to be prepared for treatment (previously treated for NTM , undergoing immune suppressive chemo, other immune suppression conditions, transplant recipients, etc.) particularly if there is relatively normal outdoor activity. That would probably reach 1/3 of the estimated US market. Then there would be Europe, Asia and other developed countries that could pay the freight.

      Sentiment: Strong Buy

    • At least 500 million per annum, according to Insmed's calculations.

      Sentiment: Strong Buy

13.21+0.03(+0.23%)Sep 19 4:15 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
NYSEFri, Sep 19, 2014 4:04 PM EDT
NYSEFri, Sep 19, 2014 4:02 PM EDT